Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry
vs
history
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry
vs
history
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.

Ratios

vs
industry
vs
history
PE Ratio 25.32
IHE's PE Ratio is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. IHE: 25.32 )
Ranked among companies with meaningful PE Ratio only.
IHE' s PE Ratio Range Over the Past 10 Years
Min: 0  Med: 0 Max: 30.97
Current: 25.32
0
30.97
PE Ratio without NRI 25.32
IHE's PE Ratio without NRI is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. IHE: 25.32 )
Ranked among companies with meaningful PE Ratio without NRI only.
IHE' s PE Ratio without NRI Range Over the Past 10 Years
Min: 0  Med: 0 Max: 30.97
Current: 25.32
0
30.97
PB Ratio 2.90
IHE's PB Ratio is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. IHE: 2.90 )
Ranked among companies with meaningful PB Ratio only.
IHE' s PB Ratio Range Over the Past 10 Years
Min: 0  Med: 0 Max: 3.23
Current: 2.9
0
3.23

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 0.89
IHE's Dividend Yield % is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. IHE: 0.89 )
Ranked among companies with meaningful Dividend Yield % only.
IHE' s Dividend Yield % Range Over the Past 10 Years
Min: 0  Med: 0 Max: 1.1
Current: 0.89
0
1.1
5-Year Yield-on-Cost % 0.89
IHE's 5-Year Yield-on-Cost % is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. IHE: 0.89 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
IHE' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0  Med: 0 Max: 1.1
Current: 0.89
0
1.1

More Statistics

Short Percentage of Float0.00%
52-Week Range $129.41 - 156.52
Shares Outstanding (Mil)4,750,000.00
» More Articles for IHE

Headlines

Articles On GuruFocus.com
JPMorgan Increases Quarterly Dividend Mar 27 2017 
Just Buy It Mar 27 2017 
Quest for the Holy Grail: The Fair Value of the Equity Market Mar 27 2017 
How to Estimate Future Growth at a Predictable Company Mar 27 2017 
GMO White Paper: Six Impossible Things Before Breakfast Mar 27 2017 
Net-Nets From Hong Kong Mar 27 2017 
Insider Invests in Crimson Wine Group Mar 27 2017 
Dow-DuPont Merger Granted Conditional Approval by EU Mar 27 2017 
Insider Invests in L.B. Foster Mar 27 2017 
GM February Sales Remain Dull in China, but Outlook Is Bright Mar 27 2017 

More From Other Websites
Should You Buy Pharma ETFs Now? Mar 15 2017
Johnson & Johnson’s Business Segment Performance Mar 13 2017
Why Health Care Is The Top Sector Of 2017 Mar 08 2017
Analysts Scratch Their Heads Over Trump Drug Price Tweet Mar 07 2017
Trump Tweets And Drug Stocks Fall Mar 07 2017
Healthcare ETFs in Focus on Obamacare Replacement Plan Mar 07 2017
Trump's Latest Drug Pricing Tweet Hits Biotech Stocks Mar 07 2017
How These Recent Developments Could Affect Mylan Mar 06 2017
Pfizer’s Products with Falling Revenues in 4Q16 Feb 27 2017
Wall Street Analysts’ Estimates for Merck & Co. Feb 24 2017
Merck & Co. Reported Flat Operational Revenues in 4Q16 Feb 22 2017
Q4 Earnings Faring Well for Pharma ETFs Feb 06 2017
Novartis’s 4Q16 Earnings Meet Analysts’ Estimates Feb 01 2017
How to Play Pfizer's Fourth-Quarter Results With ETFs Feb 01 2017
Eliquis: Bristol-Myers Squibb’s Key Cardiovascular Drug Jan 31 2017
Bristol-Myers Squibb: 4Q16 Earnings Show Growth Jan 30 2017
What Are Analysts’ Future Estimates for Johnson & Johnson? Jan 30 2017
Johnson & Johnson Reports Growth in 4Q16 Jan 26 2017
How Did JNJ’s Pharmaceuticals Segment Perform in 4Q16? Jan 20 2017
What Lies Ahead for Pharma ETFs? Jan 19 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK